PMID- 38089455
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231213
IS  - 2770-9183 (Electronic)
IS  - 2770-9191 (Print)
IS  - 2770-9183 (Linking)
VI  - 1
IP  - 1
DP  - 2022 Jun
TI  - Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the 
      treatment of advanced breast cancer.
PG  - 25-54
LID - 10.1002/cai2.10 [doi]
AB  - Phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target 
      of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in 
      the development of breast cancer and are closely associated with the resistance 
      to endocrine therapy in advanced breast cancer. Therefore, anticancer treatment 
      targeting key molecules in this signaling pathway has become a research hotspot 
      in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR 
      inhibitors bring significant clinical benefit to patients with advanced breast 
      cancer, especially to those with hormone receptor (HR)-positive, human epidermal 
      growth factor receptor (HER) 2-negative advanced breast cancer. Alpelisib, a PI3K 
      inhibitor, and everolimus, an mTOR inhibitor, have been approved by FDA. Based on 
      their high efficacy and relatively good safety profile, an expanded indication of 
      everolimus in breast cancer has been approved by National Medical Products 
      Administration (NMPA). Alpelisib is expected to be approved in China in the near 
      future. The members of the consensus expert panel reached this consensus to 
      comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast 
      cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, 
      management of adverse reactions, and PIK3CA mutation detection, to promote the 
      understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve 
      clinical decision-making, and prolong the survival of target patient population.
CI  - (c) 2022 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on 
      behalf of Tsinghua University Press.
CN  - Society of Clinical Research of Oncology Medications of China Anticancer 
      Association
CN  - Breast Cancer Expert Committee of National Cancer Quality Control Center
CN  - Boao Cancer Innovation Institute
LA  - eng
PT  - Journal Article
DEP - 20220621
PL  - England
TA  - Cancer Innov
JT  - Cancer innovation
JID - 9918713888606676
PMC - PMC10686175
OTO - NOTNLM
OT  - PI3K/AKT/mTOR inhibitors
OT  - breast cancer
COIS- All authors declare that there is no conflict of interest except Professor Fei 
      Ma, Professor Binghe Xu, Professor Haili Qian, and Professor Jiuda Zhao, who are 
      members of the Cancer Innovation Editorial Board. To minimize bias, they were 
      excluded from all editorial decision-making related to the acceptance of this 
      article for publication.
EDAT- 2022/06/21 00:00
MHDA- 2022/06/21 00:01
PMCR- 2022/06/21
CRDT- 2023/12/13 12:51
PHST- 2022/04/05 00:00 [received]
PHST- 2022/05/05 00:00 [accepted]
PHST- 2022/06/21 00:01 [medline]
PHST- 2022/06/21 00:00 [pubmed]
PHST- 2023/12/13 12:51 [entrez]
PHST- 2022/06/21 00:00 [pmc-release]
AID - CAI210 [pii]
AID - 10.1002/cai2.10 [doi]
PST - epublish
SO  - Cancer Innov. 2022 Jun 21;1(1):25-54. doi: 10.1002/cai2.10. eCollection 2022 Jun.